Adults with type 2 diabetes who raised their Ozempic dose from 1 mg to 2 mg had a 6% lower relative risk of death, heart attack, or stroke than those who switched to Mounjaro, according to a real-world analysis that Novo Nordisk announced on Sept. 29 at the European diabetes meeting in Milan. Novo Nordisk makes Ozempic and funded the work. Eli Lilly makes Mounjaro.
The finding speaks to a real decision many patients face. When blood sugar is not yet at goal on Ozempic 1 mg, doctors often choose between a higher dose of the same drug and a switch to tirzepatide, the active ingredient in Mounjaro.
